Nevro Profit Margin 2013-2022 | NVRO

Current and historical gross margin, operating margin and net profit margin for Nevro (NVRO) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Nevro net profit margin as of September 30, 2022 is -2.01%.
Nevro Annual Profit Margins
Nevro Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $1.556B $0.387B
Nevro Corp. is a medical device company which engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain, primarily in the leg. The company is known for developing and commercializing the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Additionally, the company's HF10 therapy provides long-lasting relief from chronic back and leg pain. Nevro's flagship Senza SCS system has been consistently driving the top line. Since its commercial launch in the United States, the system raked in significant revenues. These apart, Senza is commercially available in Europe since 2010 and in Australia since 2011.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $214.645B 22.45
Edwards Lifesciences (EW) United States $46.932B 32.30
Alcon (ALC) Switzerland $33.321B 28.69
STERIS (STE) Ireland $18.019B 22.42
Teleflex (TFX) United States $10.587B 17.18
Fresenius Medical Care AG KGaA (FMS) Germany $8.996B 9.03
Penumbra (PEN) United States $7.452B 1783.82
Globus Medical (GMED) United States $7.103B 36.11
Integer Holdings (ITGR) United States $2.367B 19.00
Glaukos (GKOS) United States $2.263B 0.00
Paragon 28 (FNA) United States $1.534B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.246B 17.74
Artivion (AORT) United States $0.520B 0.00